Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Moderna, Inc. < Previous 1 2 3 4 5 Next > Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses July 29, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Product Safety Tickers MRNA EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union July 22, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Tickers MRNA Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years July 18, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Tickers MRNA Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years) July 14, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Tickers MRNA Moderna to Report First Quarter Financial Results on Wednesday, August 3, 2022 July 13, 2022 From Moderna, Inc. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Tickers MRNA Moderna Announces First Participant Dosed in a Phase 1 Trial of its Nipah Virus mRNA Vaccine, mRNA-1215 July 12, 2022 From Moderna, Inc. Via AccessWire Tickers MRNA Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared To Currently Authorized Booster July 11, 2022 From Moderna, Inc. Via AccessWire Exposures Product Safety Tickers MRNA Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5 June 22, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Tickers MRNA Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom June 21, 2022 From Moderna, Inc. Via AccessWire Tickers MRNA Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older June 17, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Product Safety Tickers MRNA Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron June 08, 2022 From Moderna, Inc. Via AccessWire Tickers MRNA Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010) June 07, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Tickers MRNA Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement June 02, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Tickers MRNA Moderna to Present at Upcoming Conferences in June 2022 June 01, 2022 From Moderna, Inc. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Tickers MRNA Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna May 31, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Tickers MRNA TAK Moderna to Present at the UBS 2022 Global Healthcare Conference May 18, 2022 From Moderna, Inc. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Tickers MRNA IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program May 18, 2022 From Moderna, Inc. Via AccessWire Tickers MRNA Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day May 17, 2022 From Moderna, Inc. Via AccessWire Tickers MRNA Moderna to Host Annual Science and Technology Day on May 17, 2022 May 09, 2022 From Moderna, Inc. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Tickers MRNA Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates May 04, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Tickers MRNA Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union April 29, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Tickers MRNA Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada April 29, 2022 From Moderna, Inc. Via AccessWire Tickers MRNA Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age April 28, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Tickers MRNA Arpa Garay Joins Moderna as Chief Commercial Officer April 27, 2022 From Moderna, Inc. Via AccessWire Tickers MRNA Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform April 19, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Tickers MRNA Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022 April 13, 2022 From Moderna, Inc. Via AccessWire Tickers MRNA Jorge Gomez Joins Moderna as Chief Financial Officer April 11, 2022 From Moderna, Inc. Via AccessWire Tickers MRNA Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates April 11, 2022 From Moderna, Inc. Via AccessWire Tickers MRNA IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies April 07, 2022 From Moderna, Inc. Via AccessWire Topics Death Exposures COVID-19 Death Tickers MRNA Moderna Launches New Charitable Foundation April 04, 2022 From Moderna, Inc. Via AccessWire Exposures COVID-19 Tickers MRNA < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.